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Original Article

Trial of Pimavanserin in Dementia-Related
Psychosis
Pierre N. Tariot, M.D., Jeffrey L. Cummings, M.D., Sc.D.,
Maria E. Soto‑Martin, M.D., Ph.D., Clive Ballard, M.D., Deniz Erten‑Lyons, M.D.,
David L. Sultzer, M.D., Davangere P. Devanand, M.D., Daniel Weintraub, M.D.,
Bradley McEvoy, Dr.P.H., James M. Youakim, M.D.,
Srdjan Stankovic, M.D., M.S.P.H., and Erin P. Foff, M.D., Ph.D.

A BS T R AC T
BACKGROUND

Patients with dementia due to neurodegenerative disease can have dementia-related
psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear.
METHODS

We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer’s disease,
Parkinson’s disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. Patients received open-label pimavanserin for 12 weeks.
Those who had a reduction from baseline of at least 30% in the score on the Scale
for the Assessment of Positive Symptoms–Hallucinations and Delusions (SAPS–
H+D, with higher scores indicating greater psychosis) and a Clinical Global Impression–Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved) at weeks 8 and 12 were randomly assigned in a 1:1 ratio to continue
receiving pimavanserin or to receive placebo for up to 26 weeks. The primary end
point, assessed in a time-to-event analysis, was a relapse of psychosis as defined
by any of the following: an increase of at least 30% in the SAPS–H+D score and a
CGI-I score of 6 (much worse) or 7 (very much worse), hospitalization for dementia-related psychosis, stopping of the trial regimen or withdrawal from the trial for
lack of efficacy, or use of antipsychotic agents for dementia-related psychosis.
RESULTS

Of the 392 patients in the open-label phase, 41 were withdrawn for administrative
reasons because the trial was stopped for efficacy; of the remaining 351 patients,
217 (61.8%) had a sustained response, of whom 105 were assigned to receive pimavanserin and 112 to receive placebo. A relapse occurred in 12 of 95 patients (13%)
in the pimavanserin group and in 28 of 99 (28%) in the placebo group (hazard ratio,
0.35; 95% confidence interval, 0.17 to 0.73; P = 0.005). During the double-blind
phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin
group and in 41 of 112 (36.6%) in the placebo group. Headache, constipation, urinary
tract infection, and asymptomatic QT prolongation occurred with pimavanserin.
CONCLUSIONS

In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation
of the drug than with discontinuation. Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. (Funded by Acadia Pharmaceuticals; HARMONY ClinicalTrials.gov number, NCT03325556.)
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he most common causes of dementia — Alzheimer’s disease, dementia with
Lewy bodies, Parkinson’s disease dementia,
vascular dementia, and frontotemporal dementia1 — may be associated with hallucinations
and delusions.2,3 This syndrome of dementiarelated psychosis causes behavioral disturbances,
increased caregiver burden, decreased quality of
life, nursing home placement, and more rapid cognitive decline.4-7 Typical and atypical antipsychotic
agents are used off-label to manage psychotic
symptoms,8 regardless of underlying dementia
subtype, and are used cautiously in patients with
dementia with Lewy bodies owing to the risk of
worsening parkinsonism and other side effects.
Antipsychotics may have modest short-term efficacy for dementia-related psychosis9-13 but may be
associated with worsening cognition, extrapyramidal effects, sedation, falls, and metabolic abnormalities. Labels for these drugs include a
warning for increased risk of death among elderly patients. This situation has contributed to
clinical guidelines that focus on minimizing the
use of antipsychotics, discontinuing treatment
when improvement is not observed, and reassessing continued use after initial improvement.3
Pimavanserin is a serotonin-receptor modulator that acts primarily as a selective 5-hydroxytryptamine receptor subtype 2A (5-HT2A) inverse
agonist and antagonist, with lesser activity at
5-HT2C and no appreciable activity at other receptors in vitro. This profile is different from
those of conventional antipsychotics, which bind
to D2 dopamine receptors and have varying activity at other receptors, including at histaminergic and muscarinic receptors.14
In a 6-week trial of pimavanserin for the
treatment of hallucinations and delusions associated with Parkinson’s disease–related psychosis,15 a subgroup of patients with cognitive impairment had a change from baseline in the
psychosis score with pimavanserin that was
better than the change observed in cognitively
unimpaired patients.16 In a brief, double-blind,
placebo-controlled trial involving patients with
possible or probable Alzheimer’s disease–related
psychosis, more than half of whom also had
cerebrovascular disease, pimavanserin resulted
in a larger effect in patients with more severe
psychosis.17
On the basis of these preliminary findings in
patients with psychosis due to Parkinson’s disease
or Alzheimer’s disease, the current HARMONY
310
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trial was initiated as a phase 3, randomized discontinuation trial of the safety and efficacy of
pimavanserin for the treatment of delusions and
hallucinations associated with several common
forms of dementia. The randomized discontinuation design has been used in a trial of risperidone involving patients with Alzheimer’s disease
and behavioral complications.18 This design addresses the question of whether treatment with
pimavanserin would confer sustained benefits
with respect to psychosis in patients with an
initial response to the drug; the design also
translates to decisions about medication discontinuation and minimizes exposure to ineffective
therapy.

Me thods
Trial Design and Oversight

The trial was conducted at 101 clinical sites in
North America, eastern and western Europe, and
Latin America from August 2017 through October 2019. The trial included a 5-week screening
period, a 12-week open-label period, a doubleblind treatment period of up to 26 weeks, and a
4-week safety follow-up period (Fig. S1 in the
Supplementary Appendix, available with the full
text of this article at NEJM.org). During screening, patients received brief psychosocial therapy,19 a simple psychological therapy tailored to
each patient and partner to encourage frequent
social interaction and engagement in activities
of interest. This technique was used to follow
best practices that encourage initiation of nonpharmacologic intervention for dementia and
psychosis and to ensure that only patients with
persistent psychosis that warranted pharmacologic treatment were enrolled.
Open-label treatment was initiated with pimavanserin at a dose of 34 mg once daily; dose
reduction to 20 mg daily on the basis of side
effects was permitted from weeks 1 to 4, after
which the dose remained fixed for the remainder of the open-label phase. Patients who met
prespecified criteria for treatment response were
randomly assigned to continue receiving pimavanserin at their final open-label dose or to
receive placebo and were regularly evaluated
for relapse of psychosis. Identical tablets and
packaging were provided for pimavanserin and
placebo.
A pregenerated permuted-block schedule was
used to randomly assign patients in a 1:1 ratio

nejm.org

July 22, 2021

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF NEVADA LAS VEGAS on October 28, 2021. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.

Pimavanserin in Dementia-Related Psychosis

to receive pimavanserin or placebo, with stratification according to dementia subtype (Alzhei
mer’s disease or frontotemporal dementia vs.
vascular dementia vs. Parkinson’s disease dementia or dementia with Lewy bodies) and geographic region. The investigators and site staff,
who assessed clinical responses; the members of
the adjudication committee, who determined
whether the criteria for protocol-defined relapse
were met; and sponsor personnel were unaware
of the trial-group assignments.
The trial protocol (available at NEJM.org) was
approved by an independent ethics committee or
institutional review board at each trial site and
implemented following the principles of Good
Clinical Practice derived from the Declaration of
Helsinki and in accordance with local regulations and International Council for Harmonisation guidelines. All the patients or their authorized representatives provided written informed
consent before any trial procedures.
The sponsor, Acadia Pharmaceuticals, designed
and conducted the trial, provided the active drug
and placebo, and performed the statistical analysis. All the authors vouch for the completeness
and accuracy of the data, for the complete reporting of adverse events, and for the fidelity of
the trial to the protocol. The first draft of the
manuscript was written primarily by the last
author, with assistance from a medical writer
who was paid by the sponsor. There were confidentiality agreements in place between the authors and the sponsor, but there were no restrictions on the academic authors in submitting the
trial results for publication.
Patients

Adults 50 to 90 years of age were eligible if they
met criteria for dementia (National Institute on
Aging–Alzheimer’s Association20) and met clinical criteria for one or more of the following:
Parkinson’s disease dementia,21 dementia with
Lewy bodies,22 possible or probable Alzheimer’s
disease,20 frontotemporal dementia,23 or vascular
dementia.24 Patients were required to have a
score of 6 to 24 on the Mini–Mental State Examination (MMSE; range, 0 to 30; with higher
scores indicating better performance),25 psychotic
symptoms for at least 2 months, and a care partner who was able to reliably report patient symptoms. At screening and baseline, patients were
required to have a total score on the Scale for the
Assessment of Positive Symptoms (SAPS)–Haln engl j med 385;4

lucinations and Delusions (SAPS–H+D) of 10 or
more,26 a SAPS–H+D global rating subscore of
4 or more, and a Clinical Global Impression–
Severity (CGI-S)27 score of 4 or more (range, 1 to 7,
with higher scores indicating greater impairment). The SAPS–H+D is a subset of the SAPS,
which was devised for the assessment of schizophrenia symptoms; the range is 0 to 100, and
the scale contains 7 hallucination items (6 individual items and 1 global item) and 13 delusion
items (12 individual items and 1 global item),
each with a range of 0 to 5 and with higher
scores indicating more severe symptoms.26 Patients who were receiving an acetylcholinesterase
inhibitor or memantine had to be receiving a
stable dose for 12 weeks before screening, and the
use of antipsychotics was prohibited for 2 weeks or
five half-lives before baseline and during the
trial. Full eligibility criteria are provided in the
protocol.
Trial Assessments

The SAPS–H+D and CGI-S scores were assessed
at each clinic visit in the open-label and doubleblind phases. In the double-blind phase, clinic
visits were at weeks 13, 14, 16, 18, 22, 26, 30, 34,
and 38. Physical and neurologic examination
with vital signs, clinical laboratory testing, and
12-lead electrocardiography were performed at
screening and during the open-label and doubleblind phases (Fig. S1). The MMSE and Global
Clinician Assessment of Suicidality were conducted at each clinic visit, and the score on the
Extrapyramidal Symptom Rating Scale–Abbreviated (ESRS-A; range, 0 to 120, with higher
scores indicating greater motor dysfunction)28
was assessed at baseline, week 12 of the openlabel phase, and at each visit during the doubleblind phase.
Response criteria were assessed at weeks 8 and
12 of the open-label phase, and response was
required at both visits in order for the patient to
proceed in the trial; thus, the week 12 population was enriched with patients who had a response to pimavanserin. Response was defined
as both a reduction (improvement) from baseline
of at least 30% in the SAPS–H+D total score and
a CGI–Improvement (CGI-I) score27 of 1 (very
much improved) or 2 (much improved) relative
to baseline at both weeks 8 and 12. Patients who
met these criteria entered the double-blind phase.
Assessment for relapse occurred throughout
the double-blind phase. Discontinuations in the
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double-blind phase were adjudicated by an inde- robust sandwich variance–type estimator.29 We
pendent committee to determine whether the tested the assumptions of the primary analysis
criteria for protocol-defined relapse were met.
with the use of a global goodness-of-fit test
based on Schoenfeld residuals. There was no
End Points
evidence that the assumptions were violated for
The primary end point was the time from ran- the primary and key secondary end points. Data
domization to relapse of psychosis, as defined as for patients who did not have a relapse event
one or more of the following: an increase from were censored at the time of their last assessbaseline (double-blind phase) of at least 30% in ment before the date of data cutoff for the inthe SAPS–H+D total score and a CGI-I score of terim analysis. The secondary end point, time to
6 (much worse) or 7 (very much worse), hospital- trial discontinuation for any reason, was tested
ization due to dementia-related psychosis, stop- at the same alpha level and analyzed with the
ping the trial regimen or withdrawal from the use of the Cox regression model as described for
trial owing to lack of efficacy, or the use of the primary end point. A hierarchical testing
other antipsychotics for the treatment of demen- procedure was used to control the overall type I
tia-related psychosis. The data and safety moni- error rate for the primary and secondary end
toring board interrogated the data at the interim points at a significance level of P<0.0066 for
analysis to determine whether prespecified effi- each step. There was no plan for imputation of
missing data; however, a sensitivity analysis was
cacy stopping criteria had been met.
The secondary end point was the time from planned to investigate the assumption of noninrandomization to trial discontinuation for any formative censoring for the primary efficacy end
reason. Exploratory end points included the CGI-I point that imputed possible outcomes for the
score and the change from baseline in the double- patients who had discontinued participation in
blind phase in scores on the following scales: the trial without having had a relapse, as well as
SAPS–H+D, SAPS–Hallucinations (SAPS-H), SAPS– additional sensitivity analyses that included
Delusions (SAPS-D), CGI-S, Zarit Burden Inter- events up to trial discontinuation and the end of
view, Karolinska Sleepiness Scale, and EuroQol the trial. The statistical analysis plan is available
Group 5-Dimension 5-Level questionnaire. (De- with the protocol at NEJM.org.
tails on these scales are provided in Section 6.2
in the protocol.)

R e sult s

312

Statistical Analysis

Open-Label Phase

The sample-size calculation assumed 75 postrandomization relapse events on the basis of an
assumed hazard ratio of 0.47, an overall twosided alpha level of 0.05, a power of 90%, and
use of the O’Brien–Fleming stopping boundary
for a single interim analysis. A two-sided P value
of 0.0066 for the hazard ratio for the betweengroup difference in time to relapse was established as the value that justified stopping the
trial at the interim analysis.
The primary efficacy analysis was based on
the intention-to-treat population, defined as all
the patients who underwent randomization. The
time from randomization to relapse in the double-blind phase was compared between trial
groups with the use of a Cox regression model
with covariates for trial-group assignment, dementia strata, and geographic region and with a

A total of 794 patients were screened during
approximately 24 months of trial enrollment
(Fig. 1), and 392 patients were enrolled in the
open-label phase. The distribution of dementia
diagnoses was as follows: 66.3% of the patients
had Alzheimer’s disease, 15.1% had Parkinson’s
disease dementia, 9.7% had vascular dementia,
7.1% had dementia with Lewy bodies, and 1.8%
had frontotemporal dementia. The mean (±SD)
age of the enrolled patients was 74.5±8.3 years,
the mean duration of cognitive impairment was
4.3±2.8 years, 95.2% of the patients were living
at home (Table 1), and 81.6% had both delusions
and hallucinations at baseline. The mean MMSE
score was 16.7±4.7. The mean baseline SAPS–
H+D score was 24.4±9.2, and the mean CGI-S
score for psychosis was 4.7±0.7, consistent with
moderate psychosis. A total of 46.4% of the pa-
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794 Patients were screened

392 Were included in the open-label phase

41 Were withdrawn from the trial
for administrative reasons
134 Discontinued the trial early
70 Had lack of response
27 Had an adverse event
17 Withdrew consent
5 Did not adhere to trial regimen
4 Had a protocol violation
1 Died
1 Was lost to follow-up
1 Was receiving prohibited medication
8 Had other reason

217 Underwent randomization

105 Were assigned to receive pimavanserin

112 Were assigned to receive placebo

35 Were withdrawn from the trial
for administrative reasons

31 Were withdrawn from the trial
for administrative reasons

26 Discontinued the trial
early
15 Had a relapse
3 Had an adverse event
1 Received prohibited
medication
6 Withdrew consent
1 Had other reason

46 Discontinued the trial
early
34 Had a relapse
1 Had an adverse event
1 Did not adhere to trial
regimen
1 Was withdrawn by
physician
4 Withdrew consent
5 Had other reason

44 Completed 26 wk of the trial

35 Completed 26 wk of the trial

Figure 1. Screening, Randomization, and Follow-up.
Reasons for screening failure included (in order of frequency) criteria for severity of psychosis not being met, electrocardiographic criteria not being met, laboratory exclusions, criteria for Mini–Mental State Examination score not
being met, other reasons, withdrawal of consent during screening period, investigator or medical monitor judgment,
use of prohibited medication, and other inclusion criteria not being met or exclusion criteria being met. Formal
response criteria were assessed at weeks 8 and 12 of the open-label phase. Patients who did not meet the full response criteria at either of those visits were withdrawn from the trial, according to the protocol, and entered the
safety follow-up period. Administrative withdrawal of patients occurred when patients were ongoing in the open-
label or double-blind phase at the time of the interim analysis and trial termination for positive efficacy. Because
41 patients were withdrawn for administrative reasons before being permitted to reach week 8, week 12, or both in
the trial, only 351 patients were eligible to undergo randomization.
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic

Open-Label Phase†
Pimavanserin
(N = 392)

Age — yr
Mean
Range
Female sex — no. (%)
White race — no./total no. (%)‡
Hispanic or Latino ethnic group — no./total no. (%)‡
Living at home — no. (%)
Age at onset of cognitive impairment — yr
Duration of cognitive impairment — yr
History of psychotic symptoms — no./total no. (%)
Auditory hallucinations
Visual hallucinations
Delusions
Primary dementia subtype — no. (%)
Alzheimer’s disease
Dementia with Lewy bodies
Frontotemporal dementia
Parkinson’s disease dementia
Vascular dementia
Geographic region — no. (%)
North America
Latin America
Eastern Europe
Western Europe
Antidementia drug use — no. (%)§
Any
Acetylcholinesterase inhibitor
Antidepressant use — no. (%)
MMSE total score¶
SAPS–H+D score‖
CGI-S score**

74.5±8.3
52–90
229 (58.4)
371/384 (96.6)
86/384 (22.4)
373 (95.2)
70.6±8.9
4.3±2.8

Double-Blind Phase
Pimavanserin
(N = 105)

Placebo
(N = 112)

73.8±8.4
74.9±8.6
53–89
52–90
62 (59.0)
69 (61.6)
103/105 (98.1) 107/109 (98.2)
25/105 (23.8)
26/109 (23.9)
94 (89.5)
109 (97.3)
70.1±9.1
71.2±9.2
4.2±2.2
4.2±3.1

287/382 (75.1)
302/382 (79.1)
319/382 (83.5)

81/101 (80.2)
77/101 (76.2)
77/101 (76.2)

92/111 (82.9)
92/111 (82.9)
96/111 (86.5)

260 (66.3)
28 (7.1)
7 (1.8)
59 (15.1)
38 (9.7)

67 (63.8)
6 (5.7)
1 (1.0)
19 (18.1)
12 (11.4)

70 (62.5)
4 (3.6)
2 (1.8)
23 (20.5)
13 (11.6)

118 (30.1)
27 (6.9)
209 (53.3)
38 (9.7)

28 (26.7)
7 (6.7)
65 (61.9)
5 (4.8)

29 (25.9)
9 (8.0)
67 (59.8)
7 (6.2)

273 (69.6)
172 (43.9)
81 (20.7)
16.7±4.7
24.4±9.2
4.7±0.7

81 (77.1)
49 (46.7)
14 (13.3)
18.3±5.4
5.0±5.3
2.3±1.0

72 (64.3)
42 (37.5)
23 (20.5)
17.9±5.9
5.2±5.4
2.3±1.0

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
†	The patients who did not undergo randomization had several reasons for not doing so, including 41 patients who
were withdrawn for administrative reasons at the time of trial discontinuation and who were therefore not given the
opportunity to complete the open-label phase. The 175 patients who did not undergo randomization, in aggregate,
had the following characteristics: female sex, 56.0%; mean (±SD) age, 74.6±8.0; White race, 94.7%; mean (±SE) score
on the Mini–Mental State Examination (MMSE) (described below), 16.5±5.1; and mean (±SE) score on the Scale for
the Assessment of Positive Symptoms–Hallucinations and Delusions (SAPS–H+D) (described below), 23.1±8.7.
‡	Race and ethnic group were determined by site staff or by the patient or care partner.
§	Antidementia drugs included acetylcholinesterase inhibitors, memantine, or both. The use of an acetylcholinesterase
inhibitor alone or in a combination pill is noted as a subcategory.
¶	The MMSE is a brief 30-point questionnaire that is used to quantitatively assess cognition.25 Scores range from 0 to
30, with higher scores indicating higher performance.
‖	The SAPS–H+D consists of 20 items, including 7 hallucination items (6 individual items and 1 global item) and 13
delusion items (12 individual items and 1 global item). Scores on each item range from 0 to 5 (total scores range
from 0 to 100, with higher scores indicating a greater degree of psychosis).
**	The Clinical Global Impression–Severity (CGI-S) scale is a clinician-rated, 7-point scale that is designed to rate the
severity of the patient’s hallucinations and delusions at the time of assessment using the investigator’s judgment and
past experience with patients who have the same disorder (i.e., dementia-related psychosis).27 Scores range from 1 to
7, with higher scores indicating greater impairment.
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tients were taking at least five concomitant
medications, and 46.9% had at least five coexisting medical conditions.
Pimavanserin at a dose of 20 mg was administered to 31 of 392 patients (7.9%) in the openlabel phase, and the 34-mg dose was administered to the other patients. A total of 41 patients
remained in the open-label portion of the trial at
the time of trial discontinuation and were withdrawn for administrative reasons. Of 351 remaining eligible patients, 217 (61.8%) had a
sustained response and were randomly assigned
to continue receiving pimavanserin or to receive
placebo. A total of 70 patients (19.9%) did not
meet the criteria for a response at week 8, week
12, or both and were not carried over to the
randomized portion of the trial; 27 (7.7%) discontinued owing to an adverse event; 1 (0.3%)
died; and 36 had other reasons for discontinuing
(Fig. 1).
The mean SAPS–H+D scores at weeks 2, 4,
and 8 of the open-label phase are shown in Figure S2A. Among patients who were assessed at
week 12, there was a 75.2% mean reduction
from baseline in the SAPS–H+D score (Table S1).
Changes from baseline in the open-label phase
through week 12 in the SAPS-H, SAPS-D, and
CGI-S scores are also shown in Table S1. The
proportion of patients who met full response
criteria increased over time (Fig. S2B).
Double-Blind Phase

ble-blind phase (44 in the pimavanserin group
and 35 in the placebo group), and 66 patients (35
in the pimavanserin group and 31 in the placebo
group) who remained in the double-blind portion were withdrawn for administrative reasons
because the trial was stopped early at the interim analysis (Fig. 1).
At the time of the interim analysis, the frequency of relapse was 13% in the pimavanserin
group and 28% in the placebo group (hazard
ratio for time to relapse, 0.35; 95% confidence
interval [CI], 0.17 to 0.73; P = 0.005). The significance level for the Cox regression analysis
was below the prespecified stopping boundary
of 0.0066, and the trial was stopped (Table 2).
The risk of relapse over time is shown in Figure 2. Prespecified sensitivity analyses, including in the full enrolled population and per-protocol population, are shown in Table S2. Trial
discontinuation for any reason occurred in 21
patients (22%) in the pimavanserin group and in
38 patients (38%) in the placebo group (hazard
ratio for time to trial discontinuation for any
reason, 0.45; 95% CI, 0.26 to 0.79; P = 0.005)
(Table 2). There were no missing data for the
primary or secondary end points.
To assess the effect on specific measures
known to be affected by antipsychotics in this
trial, patients were regularly assessed for cognitive function (with the use of the MMSE) and
motor function (with the use of the ESRS-A).
During the open-label phase, the mean (±SE)
change in the total MMSE score was 1.0±0.2
points, and the mean change from baseline in
the ESRS-A score was −0.7±0.2 points, with both
changes indicating improvement (Figs. S4 and
S5). During the double-blind phase, the mean
change in the MMSE score did not differ substantially between patients who received pimavanserin and those who received placebo, and
the mean change from baseline was 1.2±0.5 in
patients treated with pimavanserin for the 38week duration of the trial (Fig. S4). During the
double-blind phase, the mean change in the
ESRS-A score at 26 weeks was −0.9±0.6 with
pimavanserin and −0.4±0.3 with placebo, favoring pimavanserin (Fig. S5).

At the time of the interim analysis, 194 patients
had undergone randomization (95 to pimavanserin and 99 to placebo); at the time of trial discontinuation, 23 additional patients had entered
the double-blind phase (total, 105 in the pimavanserin group and 112 in the placebo group).
Disease characteristics were similar in the two
trial groups (Table 1). The median duration of
exposure in the double-blind phase was 17.7 weeks
with pimavanserin and 10.9 weeks with placebo.
By the end of the trial, 72 patients (26 in the
pimavanserin group and 46 in the placebo
group) had discontinued the trial early during the
double-blind phase; the most common reasons
were relapse of psychosis (15 patients in the pimavanserin group and 34 in the placebo group) and
withdrawal of consent (6 patients in the pima- Adverse Events and Safety
vanserin group and 4 in the placebo group). A During the open-label phase, 142 patients (36.2%)
total of 79 patients completed the 26-week dou- had a treatment-emergent adverse event, defined
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Table 2. Cox Proportional-Hazards Regression Analysis of the Primary and Secondary End Points.*
End Point

Pimavanserin (N = 95)

Placebo (N = 99)

Hazard Ratio (95% CI)

P Value

28 (28)

0.35 (0.17–0.73)

0.005

0.45 (0.26–0.79)

0.005

Primary end point: relapse of psychosis
Patients who had a relapse event — no. (%)

12 (13)

Patients with censored data — no. (%)

83 (87)

71 (72)

Completed wk 26 without a relapse

37 (39)

28 (28)

9 (9)

10 (10)

37 (39)

33 (33)

Patients who discontinued for any reason — no. (%)

21 (22)

38 (38)

Patients with censored data — no. (%)

74 (78)

61 (62)

Completed wk 26 without a relapse

37 (39)

28 (28)

Were continuing in trial at time of data cutoff

37 (39)

33 (33)

Prematurely discontinued before wk 26
Were continuing in trial at time of data cutoff
Secondary end point: trial discontinuation

*	Shown are the results at the interim analysis among the 95 patients who were randomly assigned to continue receiving pimavanserin and
the 99 patients who were assigned to receive placebo during the double-blind phase. The primary and secondary end points, which were
assessed in time-to-event analyses, were tested hierarchically at the two-sided 0.0066 level to control trial-wise type I error, with relapse of
psychosis being tested first.

as an adverse event with an onset on or after the
date of the first trial dose and no later than the
date of the last trial dose plus 30 days. Such
events that occurred in more than 2% of the
patients in the open-label phase were urinary
tract infection (in 5.1% of patients), constipation
(in 2.6%), and hypertension (in 2.3%) (Table 3).
Serious adverse events occurred in 20 patients
(5.1%) in the open-label phase (Table S3). One
patient (0.3%) died from suspected myocardial
infarction that was considered by the investigator to be unrelated to pimavanserin. In addition
to the investigator’s opinion, the case was internally reviewed by the sponsor’s pharmacovigilance group and was also reviewed by the independent data and safety monitoring board;
neither group proposed modification to the investigator’s determination of causality. No clinically significant mean changes in clinical laboratory values or vital signs were observed. The
mean (±SE) prolongation of the corrected QT
interval, calculated with the use of Fridericia’s
formula (QTcF), during the open-label phase was
5.4±0.9 msec; 1 patient (0.3%) had an asymptomatic increase in the QTcF of more than 60 msec
with pimavanserin. In total, five adverse events
involving an asymptomatic prolongation of the
QT interval were reported with pimavanserin (two
in the open-label phase and three in the doubleblind phase), affecting 1.3% of the patients.
Common adverse events (occurring in ≥3% of
the patients in either group) were headache (in
316
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9.5% of patients in the pimavanserin group and
in 4.5% in the placebo group), urinary tract infection (in 6.7% and 3.6%, respectively), and
nasopharyngitis (in 1.0% and 3.6%) (Table 3).
Among all the patients receiving pimavanserin
during the trial, the most common adverse
events were constipation (in 3.1%), headache (in
4.1%), and urinary tract infection (in 6.4%). In
the double-blind phase, the incidence of serious
adverse events (Table S4) and adverse events
leading to trial discontinuation (Table 3) was
similar in the two trial groups. One patient in
the pimavanserin group died during the doubleblind phase from septic and metabolic encephalopathy caused by a dental abscess. No clinically
significant differences were observed between
the pimavanserin group and the placebo group
in mean laboratory values or vital signs during
this phase of the trial. Two patients (one in each
group) had asymptomatic QTcF values greater
than 500 msec.

Discussion
This randomized discontinuation trial examined
sustained response to pimavanserin treatment
followed by the effect of treatment discontinuation on recurrence of psychosis in patients with
several types of neurodegenerative disease. After
randomization, the percentage of patients who
had a relapse of psychosis was 13% among those
who continued to receive pimavanserin and 28%
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Figure 2. Relapse of Psychosis and Trial Discontinuation.
Shown are the results at the time of the interim analysis. Panel A shows Kaplan–Meier curves for the risk of relapse,
assessed in a time-to-event analysis, during the double-blind phase among the 95 patients who had been randomly
assigned to continue receiving pimavanserin and the 99 patients who had been assigned to receive placebo. Analysis of the differences in Kaplan–Meier probabilities at weeks 1, 2, 4, 8, 12, 18, and 26 showed statistical significance
of the separation at the nominal 5% level at week 4 and for all time points thereafter. Panel B shows Kaplan–Meier
curves for trial discontinuation for any reason, also assessed in a time-to-event analysis, during the double-blind phase.

among those who were switched to placebo, with
an estimated difference of 16 percentage points.
The risk of trial discontinuation for any reason
was lower with pimavanserin than with placebo.
This trial has limitations. Requiring sustained
response in the open-label phase limited the abiln engl j med 385;4

ity to assess future treatment response in patients
who did not meet the full response criteria at
week 8. Because the trial was stopped early for
efficacy, the ability to assess clinical predictors
of relapse is diminished, and it is possible that
the active-treatment or placebo group would have
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Table 3. Adverse Events.*
Adverse Event

Open-Label Phase
Pimavanserin
(N = 392)

Double-Blind Phase
Pimavanserin
(N = 105)

Placebo
(N = 112)

number of patients (percent)
Any adverse event

142 (36.2)

43 (41.0)

41 (36.6)

Serious adverse event†

20 (5.1)

5 (4.8)

4 (3.6)

Adverse event related to pimavanserin or placebo‡

45 (11.5)

9 (8.6)

10 (8.9)

Adverse event leading to trial discontinuation

30 (7.7)

3 (2.9)

4 (3.6)

1 (0.3)

1 (1.0)

0

Anxiety

6 (1.5)

3 (2.9)

0

Asthenia

3 (0.8)

3 (2.9)

1 (0.9)

Confusional state

8 (2.0)

1 (1.0)

0

Adverse event resulting in death§
Individual adverse events¶

Constipation

10 (2.6)

2 (1.9)

1 (0.9)

Diarrhea

5 (1.3)

0

3 (2.7)

Dizziness

6 (1.5)

3 (2.9)

0

Headache

6 (1.5)

10 (9.5)

5 (4.5)

Hypertension

9 (2.3)

2 (1.9)

2 (1.8)

Nasopharyngitis

7 (1.8)

1 (1.0)

4 (3.6)

Nausea

8 (2.0)

0

2 (1.8)

Prolonged QT interval‖

2 (0.5)

3 (2.9)

0

Urinary tract infection

20 (5.1)

7 (6.7)

4 (3.6)

5 (1.3)

1 (1.0)

3 (2.7)

Weight decreased

*	Shown are treatment-emergent adverse events that occurred in at least 2% of the patients in the open-label phase or
in either trial group in the double-blind phase. A treatment-emergent adverse event is an adverse event with an onset
on or after the date of the first trial dose and no later than the date of the last trial dose plus 30 days. For patients who
underwent randomization in the double-blind phase, if the onset of the adverse event was on or after the date of first
dose in the double-blind phase, the adverse event was assigned to the double-blind phase.
†	A serious adverse event was an adverse event that met one or more of the following criteria: was fatal or life-threatening, resulted in disability or permanent damage, led to hospitalization, prolonged existing hospitalization, was a congenital anomaly or birth defect, or was medically significant. The classification of an adverse event as serious was made
by the investigator.
‡	An adverse event was considered to be related to pimavanserin or placebo by the investigator if there was a reasonable
possibility that the event may have been caused by the trial treatment under investigation. Events with a missing relationship were classified as being related.
§	A 75-year-old White man died during the open-label phase from suspected myocardial infarction, which was considered
to be unrelated to the trial drug by the investigator. An 81-year-old White man who was assigned to receive pimavanserin in the double-blind phase died from septic and metabolic encephalopathy caused by a dental abscess, which was
considered to be unrelated to drug therapy by the investigator.
¶	No significant between-group differences in adverse events were observed when tested at the 5% level.
‖	The adverse events involving prolongation of the corrected QT interval, calculated with the use of Fridericia’s formula,
involved maximum changes from baseline of 12 msec and 51 msec in two patients in the open-label phase (the former
was in a patient who discontinued the trial owing to lack of response, and the latter resolved with dose reduction) and
6 msec, 22 msec, and 77 msec in three patients in the double-blind phase (the first two resolved without intervention,
and the third remained stable until the patient discontinued the trial). All events were detected on electrocardiography
and were asymptomatic.

had additional relapse events or adverse events if
the trial had been longer. Pimavanserin has shown
efficacy in patients with hallucinations and delusions associated with Parkinson’s disease psychosis and is approved for that indication, and
approximately 15% of the patients in the trial
318
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had Parkinson’s disease, which may have skewed
the results in favor of pimavanserin. Previous
trials that involved patients with Parkinson’s
disease–related psychosis included only those with
normal cognition or with MMSE scores of 21 or
more. In contrast, 61% of the patients with Par-
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kinson’s disease in the current trial had moderate-to-severe dementia. Almost all the patients
in the trial were White. Finally, the double-blind
phase was planned for 26 weeks of follow-up of
each individual patient but was stopped early for
efficacy, which contributed to a median duration
of exposure during this phase of approximately
18 weeks in the pimavanserin group and 11 weeks
in the placebo group.
Common adverse events that occurred more
frequently with pimavanserin than with placebo
were headache, constipation, and urinary tract
infection. The mean change in QTcF in patients
who were exposed to pimavanserin in the openlabel phase was 5.4 msec, consistent with the
current labeling of the drug, and five adverse
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